









市場行情
/
股票
/
nasdaq-slno
/

Soleno Therapeutics Inc

SLNO

49.550USD

-0.220-0.44%

收盤 11/26, 16:00（美東）報價延遲15分鐘

2.26B總市值

虧損本益比TTM



Soleno Therapeutics Inc

49.550

-0.220-0.44%

概覽公司財務分析

概覽

公司

財務

分析

關於 Soleno Therapeutics Inc 公司

Soleno Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物二氮嗪膽鹼緩釋片 (DCCR) 是一種緩釋片，是一種用於治療普拉德-威利綜合徵 (PWS) 的每日一次口服藥，最近完成了其第 3 階段開發計劃。DCCR 是一種有效的 ATP 敏感鉀 (KATP) 通道激活劑。DCCR 片劑含有活性成分二氮嗪膽鹼，二氮嗪是一種苯並噻二嗪類藥物的膽鹼鹽。DCCR 的作用模式是針對大腦、胰腺和脂肪組織，有可能影響 PWS 等複雜疾病，以減少食慾、減少食物尋求、提高飽腹感、改善胰島素和瘦素抵抗並減少體脂。該公司在美國和歐盟擁有 PWS 中 DCCR 的快速通道稱號以及該藥物的孤兒藥稱號。

Soleno Therapeutics Inc簡介



公司代碼SLNO

公司名稱Soleno Therapeutics Inc

上市日期Oct 23, 2014

CEODr. Anish Bhatnagar, M.D.

員工數量92

證券類型Ordinary Share

年結日Oct 23

公司地址100 Marine Parkway, Suite 400

城市REDWOOD CITY

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編94065

電話16502138444

網址https://soleno.life/

公司代碼SLNO

上市日期Oct 23, 2014

CEODr. Anish Bhatnagar, M.D.

Soleno Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

Dr. Andrew Sinclair, Ph.D.

Independent Director

10.49K

+61.40%

Mr. Mark W. Hahn, CPA

Independent Director

10.05K

Ms. Patricia C. Hirano

Vice President - Regulatory Affairs

6.81K

-36.00%

Dr. Anish Bhatnagar, M.D.

Chairman of the Board, Chief Executive Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. James H. (Jim) Mackaness

Chief Financial Officer

90.68K

+32.66%

Dr. Michael Huang, M.D.

Senior Vice President - Clinical Development

36.82K

-11.07%

Ms. Kristen Yen

Senior Vice President - Global Clinical Operations and Patient Advocacy

28.14K

-66.09%

Ms. Dawn Carter Bir

Independent Director

16.99K

+30.70%

Mr. William G. (Bill) Harris

Independent Director

12.89K

+44.84%

Dr. Birgitte Volck, M.D., Ph.D.

Independent Director

11.04K

+56.65%

收入明細

FY2025Q2

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

32.66M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

12.15%

Janus Henderson Investors

11.28%

T. Rowe Price Associates, Inc.

7.16%

BlackRock Institutional Trust Company, N.A.

5.47%

The Vanguard Group, Inc.

5.21%

其他

58.73%

持股股東

佔比

Fidelity Management & Research Company LLC

12.15%

Janus Henderson Investors

11.28%

T. Rowe Price Associates, Inc.

7.16%

BlackRock Institutional Trust Company, N.A.

5.47%

The Vanguard Group, Inc.

5.21%

其他

58.73%

股東類型

持股股東

佔比

Investment Advisor

49.52%

Investment Advisor/Hedge Fund

44.44%

Hedge Fund

22.96%

Venture Capital

5.33%

Individual Investor

1.87%

Research Firm

1.50%

Bank and Trust

0.71%

Pension Fund

0.34%

Sovereign Wealth Fund

0.11%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

416

58.51M

108.94%

-3.11M

2025Q2

384

58.69M

110.44%

+1.14M

2025Q1

373

57.15M

113.59%

-442.82K

2024Q4

313

53.26M

117.76%

+3.04M

2024Q3

277

49.14M

121.09%

-377.00K

2024Q2

234

44.76M

117.95%

+4.14M

2024Q1

189

36.54M

114.10%

-1.05M

2023Q4

146

32.09M

102.81%

+3.37M

2023Q3

107

21.08M

166.08%

+14.34M

2023Q2

5.70M

63.31%

-1.46M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

3.23M

6.07%

+1.10M

+52.00%

Jun 30, 2025

Janus Henderson Investors

5.31M

9.99%

+167.11K

+3.25%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.42M

6.43%

+1.05M

+44.45%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.51M

4.72%

+791.68K

+46.16%

Jun 30, 2025

The Vanguard Group, Inc.

2.48M

4.67%

+619.99K

+33.33%

Jun 30, 2025

Avoro Capital Advisors LLC

2.05M

3.86%

-475.00K

-18.81%

Jun 30, 2025

Wellington Management Company, LLP

621.04K

1.17%

-72.61K

-10.47%

Jun 30, 2025

Vivo Capital, LLC

3.96M

7.45%

Aug 01, 2025

State Street Investment Management (US)

1.40M

2.64%

+235.78K

+20.17%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

SPDR S&P Biotech ETF

1.61%

Direxion Daily S&P Biotech Bull 3X Shares

0.84%

JPMorgan Healthcare Leaders ETF

0.72%

Harbor Health Care ETF

0.68%

Virtus LifeSci Biotech Clinical Trials ETF

0.61%

VictoryShares US Small Mid Cap Value Momentum ETF

0.2%

T Rowe Price Small-Mid Cap ETF

0.18%

iShares Russell 2000 Growth ETF

0.17%

JPMorgan BetaBuilders US Small Cap Equity ETF

0.17%

Fidelity Fundamental Small-Mid Cap ETF

0.16%

SPDR S&P Biotech ETF

佔比1.61%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.84%

JPMorgan Healthcare Leaders ETF

佔比0.72%

Harbor Health Care ETF

佔比0.68%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.61%

VictoryShares US Small Mid Cap Value Momentum ETF

佔比0.2%

T Rowe Price Small-Mid Cap ETF

佔比0.18%

iShares Russell 2000 Growth ETF

佔比0.17%

JPMorgan BetaBuilders US Small Cap Equity ETF

佔比0.17%

Fidelity Fundamental Small-Mid Cap ETF

佔比0.16%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

公告日期

類型

比率

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

Aug 25, 2022

Merger

15→1

常見問題

Soleno Therapeutics Inc的前五大股東是誰？



Soleno Therapeutics Inc的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：3.23M
佔總股份比例：6.07%。
Janus Henderson Investors
持有股份：5.31M
佔總股份比例：9.99%。
T. Rowe Price Associates, Inc.
持有股份：3.42M
佔總股份比例：6.43%。
BlackRock Institutional Trust Company, N.A.
持有股份：2.51M
佔總股份比例：4.72%。
The Vanguard Group, Inc.
持有股份：2.48M
佔總股份比例：4.67%。